Novo teams with OpenAI; Ideaya gets muted response to eye drug data
Source: BioPharma Dive - Latest News
Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early promise.